SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 140 filers reported holding SAREPTA THERAPEUTICS INC in Q3 2013. The put-call ratio across all filers is 1.16 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $57,416,095 | +0.0% | 473,652 | -5.5% | 0.02% | +4.3% |
| Q2 2023 | $57,408,991 | -15.0% | 501,301 | +2.3% | 0.02% | -20.7% |
| Q1 2023 | $67,568,677 | +379.7% | 490,232 | +351.0% | 0.03% | +383.3% |
| Q4 2022 | $14,086,383 | -8.7% | 108,708 | -22.1% | 0.01% | -14.3% |
| Q3 2022 | $15,432,000 | -6.5% | 139,609 | -36.6% | 0.01% | -12.5% |
| Q2 2022 | $16,497,000 | -17.2% | 220,076 | -13.7% | 0.01% | 0.0% |
| Q1 2022 | $19,926,000 | +109.9% | 255,064 | +141.9% | 0.01% | +166.7% |
| Q4 2021 | $9,494,000 | -26.6% | 105,433 | -24.6% | 0.00% | -40.0% |
| Q3 2021 | $12,935,000 | +327.5% | 139,863 | +259.3% | 0.01% | +400.0% |
| Q2 2021 | $3,026,000 | -16.2% | 38,928 | -19.7% | 0.00% | -50.0% |
| Q1 2021 | $3,612,000 | -95.8% | 48,465 | -90.3% | 0.00% | -95.0% |
| Q4 2020 | $85,138,000 | +31.2% | 499,371 | +8.1% | 0.04% | +14.3% |
| Q3 2020 | $64,901,000 | -21.3% | 462,159 | -10.1% | 0.04% | -27.1% |
| Q2 2020 | $82,456,000 | +80.4% | 514,259 | +10.1% | 0.05% | +45.5% |
| Q1 2020 | $45,704,000 | -22.3% | 467,228 | +2.5% | 0.03% | 0.0% |
| Q4 2019 | $58,795,000 | +45.2% | 455,636 | -15.2% | 0.03% | +32.0% |
| Q3 2019 | $40,490,000 | -46.1% | 537,574 | +8.7% | 0.02% | -46.8% |
| Q2 2019 | $75,159,000 | +9.8% | 494,628 | -13.9% | 0.05% | +4.4% |
| Q1 2019 | $68,467,000 | +5.4% | 574,435 | -3.5% | 0.04% | -6.2% |
| Q4 2018 | $64,937,000 | +48.4% | 595,041 | +119.6% | 0.05% | +65.5% |
| Q3 2018 | $43,755,000 | -16.8% | 270,911 | -31.9% | 0.03% | -21.6% |
| Q2 2018 | $52,562,000 | +271.0% | 397,655 | +108.0% | 0.04% | +270.0% |
| Q1 2018 | $14,166,000 | +117.0% | 191,200 | +62.9% | 0.01% | +100.0% |
| Q4 2017 | $6,529,000 | -15.4% | 117,340 | -31.0% | 0.01% | -16.7% |
| Q3 2017 | $7,718,000 | +93.5% | 170,140 | +43.8% | 0.01% | +100.0% |
| Q2 2017 | $3,988,000 | +85.9% | 118,310 | +63.3% | 0.00% | +50.0% |
| Q1 2017 | $2,145,000 | +8.0% | 72,450 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $1,987,000 | -48.4% | 72,450 | +15.5% | 0.00% | -33.3% |
| Q3 2016 | $3,853,000 | +118.3% | 62,750 | -32.2% | 0.00% | +50.0% |
| Q2 2016 | $1,765,000 | +30.9% | 92,550 | +34.0% | 0.00% | +100.0% |
| Q1 2016 | $1,348,000 | -49.4% | 69,050 | 0.0% | 0.00% | -50.0% |
| Q4 2015 | $2,664,000 | +19.1% | 69,050 | -0.9% | 0.00% | 0.0% |
| Q3 2015 | $2,236,000 | +6.6% | 69,650 | +1.1% | 0.00% | 0.0% |
| Q2 2015 | $2,097,000 | +162.5% | 68,900 | +14.5% | 0.00% | +100.0% |
| Q1 2015 | $799,000 | -18.0% | 60,200 | -10.5% | 0.00% | 0.0% |
| Q4 2014 | $974,000 | -31.4% | 67,300 | 0.0% | 0.00% | 0.0% |
| Q3 2014 | $1,420,000 | -29.2% | 67,300 | 0.0% | 0.00% | -50.0% |
| Q2 2014 | $2,005,000 | +24.0% | 67,300 | 0.0% | 0.00% | +100.0% |
| Q1 2014 | $1,617,000 | +17.9% | 67,300 | 0.0% | 0.00% | 0.0% |
| Q4 2013 | $1,371,000 | -56.9% | 67,300 | 0.0% | 0.00% | -66.7% |
| Q3 2013 | $3,179,000 | -70.1% | 67,300 | -75.9% | 0.00% | -72.7% |
| Q2 2013 | $10,646,000 | – | 279,802 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ikarian Capital, LLC | 399,400 | $35,962,000 | 5.36% |
| Avoro Capital Advisors LLC | 3,125,000 | $281,406,000 | 4.79% |
| Varenne Capital Partners | 324,661 | $29,236,000 | 4.34% |
| Evolutionary Tree Capital Management, LLC | 96,695 | $8,707,000 | 4.18% |
| Ally Bridge Group (NY) LLC | 120,000 | $10,806,000 | 3.78% |
| Casdin Capital, LLC | 1,350,000 | $121,568,000 | 3.43% |
| Ghost Tree Capital, LLC | 100,000 | $9,005,000 | 3.23% |
| GREAT POINT PARTNERS LLC | 145,405 | $13,094,000 | 2.91% |
| Camber Capital Management LP | 825,000 | $74,291,000 | 2.55% |
| Alpha DNA Investment Management LLC | 17,522 | $1,577,000 | 1.00% |